Autoimmune enteropathy in a child: response to infliximab therapy.
Vanderhoof
Jon A
JA
Department of Pediatrics, University of Nebraska Medical Center, Creighton University, Omaha, Nebraska, USA. jvanderh@unmc.edu
Young
Rosemary J
RJ
D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000473:pathology; D002908:Chronic Disease; D003967:Diarrhea / Q000209:etiology; D005500:Follow-Up Studies; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D000069285:Infliximab; D007410:Intestinal Diseases / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D010288:Parenteral Nutrition; D016559:Tacrolimus / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D000069285:Infliximab; D016559:Tacrolimus